Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

LLY US Equity

ELI LILLY & Co
NYSE+ CompareTear sheet →
Health Care · Pharmaceutical Preparations · CIK 59478 · FY ends Dec 31
$1,225.73
+42.57 (+3.60%)
USD · as of 2026-08-18 · marketstack

Clinical trials

catalyst calendar across sponsors →
2,093 registered studies · 225 active

Studies where LLY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

Of the 500 shown: 495 interventional · 5 observational · 148 with posted results

Held by 29 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, POLEN CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., +24 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 7 congress / 4 executive

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
Epidemiology and Biomarker Study in Alzheimer's DiseaseNCT07142954Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite ComponentsNon-randomized · Open-label · OtherPhase 3RecruitingOther: P-tau217 TestAlzheimer Disease3,400Jul 2033≤ 2,538 d2026-07-07
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseNCT06566170observationalTime to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS])—RecruitingDrug: Donanemab, Usual CareAlzheimer Disease6,250Feb 2033≤ 2,385 d2025-10-09
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390Time to First Occurrence of Composite Endpoint of Major Cardiovascular EventsRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Orforglipron, PlaceboAtherosclerosis Cardiovascular Disease, Chronic Kidney Disease7,140Aug 2031≤ 1,838 d2026-08-06
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisNCT03773965Number of Participants with One or More Serious Adverse Event(s) (SAEs)Open-label · TreatmentPhase 3RecruitingDrug: BaricitinibJuvenile Idiopathic Arthritis190Jul 2031≤ 1,807 d2026-08-07
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsNCT07222137Time from Baseline to Diagnosis of Stage 3 Type 1 DiabetesRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Baricitinib, PlaceboDiabetes Mellitus, Type 1150Jul 2031≤ 1,807 d2026-08-06
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)NCT07157774Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite EndpointRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Muvalaplin, PlaceboElevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)10,450Mar 2031≤ 1,685 d2026-08-07
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)NCT04844606Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical RemissionNon-randomized · Open-label · TreatmentPhase 3RecruitingDrug: Mirikizumab, MirikizumabUlcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease150Dec 2030≤ 1,595 d2026-08-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: Tirzepatide, Retatrutide, PlaceboMetabolic Dysfunction-Associated Steatotic Liver Disease4,500Aug 2030≤ 1,473 d2026-08-06
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, MetforminBreast Cancer, Solid Tumors, Adult880Jul 2030≤ 1,442 d2026-07-07
A Study of LY4175408 in Participants With Advanced CancerNCT07046923Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4175408, Pembrolizumab, Carboplatin, CisplatinCarcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer240Jul 2030≤ 1,442 d2026-06-23
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisNCT07415044Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4268989, PlaceboUlcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe1,431Jun 2030≤ 1,411 d2026-08-06
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibNCT06876649Percentage of Participants with a Grade ≥3 treatment-emergent AEsOpen-label · TreatmentPhase 4RecruitingDrug: PirtobrutinibChronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma787May 2030≤ 1,381 d2026-03-02
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaNCT06876662Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs)Open-label · TreatmentPhase 4RecruitingDrug: PirtobrutinibChronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma279May 2030≤ 1,381 d2026-03-02
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersNCT07162181Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse EventsOpen-label · TreatmentPhase 2Active, not recruitingDrug: PirtobrutinibLymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma13May 2030≤ 1,381 d2026-04-17
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT07218341Percentage of Participants with a Grade 3 or Higher Treatment-emergent Adverse Events (AEs)Non-randomized · Open-label · TreatmentPhase 4RecruitingDrug: Pirtobrutinib, IdelalisibChronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic150May 2030≤ 1,381 d2026-08-06
A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496Non-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms421Apr 2030≤ 1,350 d2026-08-06
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseNCT07571161Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Donanemab, PlaceboAlzheimer Disease140Apr 2030≤ 1,350 d2026-08-06
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Open-label · TreatmentPhase 3Not yet recruitingDrug: Orforglipron, DulaglutideDiabetes Mellitus, Type 2170Mar 2030≤ 1,320 d2026-08-19
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185Number of Participants with Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, PembrolizumabPancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor750Jan 2030≤ 1,261 d2026-07-20
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskNCT07613294Percent Change from Baseline in Noncalcified Plaque (NCP) VolumeRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Lepodisiran, PlaceboAtherosclerosis, Cardiovascular Diseases, Lipoprotein(a)252Dec 2029≤ 1,230 d2026-08-07
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractNCT07218380Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumabRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Vepugratinib, EV, Pembrolizumab · Other: PlaceboCarcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis450Oct 2029≤ 1,169 d2026-08-17
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).NCT07602582Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Donanemab, PlaceboAlzheimer Disease, Dementia, Plaque, Amyloid550Sep 2029≤ 1,138 d2026-07-07
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)NCT07247084Percent Change from Baseline in Body WeightRandomized · Open-label · TreatmentPhase 4RecruitingDrug: Tirzepatide · Other: Standard of CareObesity3,000Jul 2029≤ 1,077 d2026-07-07
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral SclerosisNCT07571174Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationOpen-label · Basic sciencePhase 1RecruitingDrug: LY4256984Amyotrophic Lateral Sclerosis32Jun 2029≤ 1,046 d2026-07-17
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)NCT07571200Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)Open-label · ScreeningPhase 1RecruitingDrug: LY4256984Amyotrophic Lateral Sclerosis32Jun 2029≤ 1,046 d2026-07-17
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598Part A: Disease-Free Survival (DFS) by Investigator AssessmentRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Olomorasib, Pembrolizumab, Durvalumab, PlaceboCarcinoma, Non-Small-Cell Lung700May 2029≤ 1,016 d2026-08-07
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336(Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, FulvestrantBreast Neoplasms, Neoplasm Metastasis800May 2029≤ 1,016 d2026-08-06
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Remternetug, PlaceboAlzheimer's Disease1,400Apr 2029≤ 985 d2025-11-20
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07654972Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4174794, LY4174794, PlaceboObesity, Overweight108Apr 2029≤ 985 d2026-07-16
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)NCT06292013Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite EndpointRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Lepodisiran Sodium, PlaceboAtherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)17,300Mar 2029≤ 955 d2026-07-20
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Open-label · TreatmentPhase 1RecruitingDrug: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracilPancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer630Mar 2029≤ 955 d2026-06-18
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Time to First Occurrence of Composite EndpointsRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, PlaceboAtherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)10,000Feb 2029≤ 924 d2026-07-20
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098Change from Baseline in Antigen Kiel (Ki-67) ExpressionRandomized · Open-label · TreatmentPhase 2RecruitingDrug: Imlunestrant, Goserelin, Tamoxifen 20 mgBreast Neoplasms600Jan 2029≤ 896 d2026-08-06
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerNCT07213804Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by InvestigatorRandomized · Open-label · TreatmentPhase 3RecruitingDrug: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, CarboplatinOvarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis1,630Nov 2028≤ 834 d2026-08-06
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: RetatrutideObesity, Overweight600Oct 2028≤ 804 d2026-06-09
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseNCT06226883Proportion of participants with endoscopic response at Week 14 as determined using the Simple Endoscopic Score-CD (SES-CD)Randomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: Placebo, MORF-057Inflammatory Bowel Diseases, Crohn's Disease385Sep 2028≤ 773 d2026-07-20
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved IndicationNCT07612267Concentration of Mirikizumab in Breast MilkOpen-label · OtherPhase 4Not yet recruitingDrug: MirikizumabLactation, Inflammatory Bowel Disease14Sep 2028≤ 773 d2026-06-15
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB)Randomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: Donanemab, PlaceboCognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid350Aug 2028≤ 743 d2026-08-06
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) ToxicitiesNon-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4337713Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma241Jul 2028≤ 712 d2026-08-06
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)NCT07222332Change from Baseline in C-peptide Area Under the Curve (AUC)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Baricitinib, PlaceboDiabetes Mellitus, Type 1300Jul 2028≤ 712 d2026-08-06
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593Percent Change from Baseline in Maximum Walking DistanceRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Orforglipron, PlaceboPeripheral Arterial Disease1,205Jun 2028≤ 681 d2026-08-06
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Eloralintide, PlaceboOverweight, Obesity900Jun 2028≤ 681 d2026-08-06
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Donanemab, PlaceboAlzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders1,500May 2028≤ 651 d2026-07-16
A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaNCT06721013Phase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1/2RecruitingDrug: Pirtobrutinib, PlaceboImmune Thrombocytopenia (ITP)68May 2028≤ 651 d2026-06-25
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)Open-label · TreatmentPhase 4RecruitingDrug: TirzepatidePsoriasis, Overweight or Obesity200May 2028≤ 651 d2026-06-03
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight ReductionRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Mirikizumab, Mirikizumab, Tirzepatide, PlaceboCrohn's Disease, Obesity or Overweight290May 2028≤ 651 d2026-08-06
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245Change from Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)Randomized · Double-masked · TreatmentPhase 2Not yet recruitingDrug: Brenipatide, Placebo, Standard of CarePulmonary Disease, Chronic Obstructive606May 2028≤ 651 d2026-08-12
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, PlaceboObesity643Apr 2028≤ 620 d2026-03-03
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight ReductionRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Mirikizumab, Mirikizumab, Tirzepatide, PlaceboUlcerative Colitis, Obesity or Overweight350Apr 2028≤ 620 d2026-08-06
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale ScoreRandomized · Single-masked · TreatmentPhase 3RecruitingDrug: Orforglipron, PlaceboOsteoarthritis800Apr 2028≤ 620 d2026-08-06
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173Annualized Asthma Exacerbation Rate Over 52 Weeks of TreatmentRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Brenipatide, Brenipatide, PlaceboAsthma531Apr 2028≤ 620 d2026-08-07
A Study of Brenipatide in Participants With Alcohol Use DisorderNCT07219953Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: LY3537031, PlaceboAlcohol Use Disorder1,100Apr 2028≤ 620 d2026-08-06
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderNCT07219966Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: LY3537031, PlaceboAlcohol Use Disorder1,100Apr 2028≤ 620 d2026-08-06
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataNCT05723198Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) ≤20Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Baricitinib, PlaceboAreata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical595Mar 2028≤ 590 d2026-07-17
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Change from Baseline in Incontinence Episode Frequency (IEF)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Orforglipron, PlaceboUrinary Incontinence,Stress1,000Mar 2028≤ 590 d2026-08-06
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY4213663, LY4213663, Placebo, PlaceboRheumatoid Arthritis (RA)141Mar 2028≤ 590 d2026-06-23
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07276958Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Single-masked · Basic sciencePhase 1RecruitingDrug: LY4298445, LY4298445Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis63Mar 2028≤ 590 d2026-07-17
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Eloralintide, PlaceboObesity, Overweight1,980Mar 2028≤ 590 d2026-08-06
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Eloralintide, PlaceboOsteoarthritis, Overweight or Obesity900Mar 2028≤ 590 d2026-08-06
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Eloralintide, PlaceboSleep Apnea, Obstructive, Obesity, Overweight800Mar 2028≤ 590 d2026-08-06
A Study of Brenipatide in Participants With Opioid Use DisorderNCT07420283Percentage of Weeks of Abstinence from Opioid Use Defined by Both Negative Urine Drug Screen (UDS) and no Self-Report of Opioid use Based on Timeline Followback (TLFB)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: Brenipatide, Placebo, BuprenorphineOpioid Use Disorder465Mar 2028≤ 590 d2026-08-06
A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Brenipatide, PlaceboDepressive Disorder, Major1,000Feb 2028≤ 559 d2026-08-06
A Study of LY4178256 in Healthy ParticipantsNCT07698210Part A: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.Randomized · Double-masked · Basic sciencePhase 1Not yet recruitingDrug: LY4178256, PlaceboHealthy Volunteers88Feb 2028≤ 559 d2026-07-13
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's DiseaseNCT06809400Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part ARandomized · Single-masked · TreatmentPhase 1RecruitingDrug: LY4006896, PlaceboParkinson Disease127Jan 2028≤ 530 d2026-04-20
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3RecruitingDrug: Eloralintide, PlaceboOverweight, Obesity1,035Jan 2028≤ 530 d2026-08-06
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseNCT05509777Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52Non-randomized · Open-label · TreatmentPhase 3RecruitingDrug: MirikizumabCrohn's Disease90Dec 2027≤ 499 d2026-08-07
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisNCT05735483Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)Non-randomized · Open-label · TreatmentPhase 3Enrolling by invitationDrug: Lebrikizumab, PlaceboAtopic Dermatitis, Eczema333Dec 2027≤ 499 d2026-07-30
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT06598943Percentage of Participants Achieving Clinical RemissionRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Eltrekibart, Mirikizumab, PlaceboUlcerative Colitis, Ulcerative Colitis Chronic143Dec 2027≤ 499 d2026-07-30
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Percent Change from Baseline in Body Mass Index (BMI)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Orforglipron, PlaceboObesity, Overweight150Dec 2027≤ 499 d2026-07-22
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationOpen-label · TreatmentPhase 3RecruitingDrug: DulaglutideType 2 Diabetes55Dec 2027≤ 499 d2026-08-07
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Donanemab, PlaceboAlzheimer Disease2,996Nov 2027≤ 468 d2026-01-21
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, PemetrexedCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis1,264Nov 2027≤ 468 d2026-07-20
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of TherapyOpen-label · TreatmentPhase 4RecruitingDrug: TirzepatidePsoriatic Arthritis, Overweight or Obesity200Nov 2027≤ 468 d2026-06-11
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)NCT07286175Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse CriterionRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Brenipatide, PlaceboBipolar Disorder400Nov 2027≤ 468 d2026-08-06
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: Brenipatide, PlaceboSchizophrenia450Nov 2027≤ 468 d2026-08-06
A Study of LY3971297 in Participants With Heart FailureNCT07547540Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Single-masked · TreatmentPhase 1Not yet recruitingDrug: LY3971297, LY3971297, Placebo, PlaceboHeart Failure, Heart Failure, Diastolic, Heart Failure, Systolic90Nov 2027≤ 468 d2026-08-10
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054Invasive Disease-Free Survival (IDFS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Imlunestrant, Tamoxifen, Anastrozole, Letrozole, ExemestaneBreast Neoplasms8,000Oct 2027≤ 438 d2026-04-02
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Tirzepatide, PlaceboObesity, Overweight15,374Oct 2027≤ 438 d2026-01-12
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Percent Change from Baseline in Body Mass Index (BMI)Randomized · Double-masked · TreatmentPhase 3RecruitingDrug: Tirzepatide, PlaceboObesity, Weight Gain300Oct 2027≤ 438 d2026-08-07
A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxelMetastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor340Oct 2027≤ 438 d2026-08-07
A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive ComplaintNCT07140744Difference in Proportion of Participants Between the Primary Care Physician (PCP) Tested Group and the PCP Control Group with at Least 1 Management ActionRandomized · Open-label · OtherNot applicableRecruitingDiagnostic test: P-tau217 · Other: Standard of CareSubjective Cognitive Impairment7,000Oct 2027≤ 438 d2025-11-03
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityNCT07438444Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationOpen-label · TreatmentPhase 4RecruitingDrug: TirzepatideDiabetes Mellitus, Type 2, Obesity, Overweight344Oct 2027≤ 438 d2026-05-19
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956Number of Participants Allocated to Each ISARandomized · Double-masked · ScreeningStudy Protocol ↗Phase 2RecruitingDrug: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo, PlaceboObesity, Overweight1,481Sep 2027≤ 407 d2026-08-06
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerNCT06229366Maximum tolerated dose (MTD)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer142Sep 2027≤ 407 d2025-12-22
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422Number of Participants Allocated to Each ISARandomized · Double-masked · ScreeningPhase 3Active, not recruitingDrug: Orforglipron, PlaceboHypertension974Sep 2027≤ 407 d2026-05-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435Change from Baseline in office Systolic Blood Pressure (SBP)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Orforglipron, PlaceboHypertension, Overweight or Obesity487Sep 2027≤ 407 d2026-05-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530Change from Baseline in office Systolic Blood Pressure (SBP)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Orforglipron, PlaceboHypertension487Sep 2027≤ 407 d2026-05-29
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093Change from Baseline in Pain Intensity Per Numeric Rating ScaleRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, PlaceboObesity, Overweight, Chronic Low Back Pain (CLBP)586Sep 2027≤ 407 d2026-07-23
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy ParticipantsNCT07046559Part A: Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4066708, Placebo, LY4066708, PlaceboHealthy, Cancer104Sep 2027≤ 407 d2026-03-03
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)NCT07545759Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of DaysRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY3537031, PlaceboIrritable Bowel Syndrome, Diarrhea531Sep 2027≤ 407 d2026-08-06
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Macupatide, Eloralintide, PlaceboOverweight, Obesity400Sep 2027≤ 407 d2026-08-06
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Orforglipron, PlaceboObesity, Overweight800Aug 2027≤ 377 d2026-07-29
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Orforglipron, PlaceboObesity, Overweight, Type 2 Diabetes600Aug 2027≤ 377 d2026-04-20
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792Number of Participants Allocated to Each StudyRandomized · Double-masked · ScreeningPhase 3Active, not recruitingDrug: Orforglipron, PlaceboObesity, Overweight, Type 2 Diabetes1,400Aug 2027≤ 377 d2026-07-31
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral SclerosisNCT07100119Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4256984, PlaceboALS (Amyotrophic Lateral Sclerosis)32Aug 2027≤ 377 d2026-03-06
A Study of LY4302814 in Healthy ParticipantsNCT07566338Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4302814, LY4302814, Placebo, PlaceboHealthy150Aug 2027≤ 377 d2026-06-16
A Study of LY3439539 in Participants With Alzheimer's DiseaseNCT07598370Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL)Open-label · Basic sciencePhase 1RecruitingDrug: LY3439539Alzheimer Disease30Aug 2027≤ 377 d2026-08-07
A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value)Randomized · Double-masked · TreatmentPhase 1RecruitingDrug: Eloralintide · Other: PlaceboOverweight, Obesity115Aug 2027≤ 377 d2026-07-16
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)NCT06657768Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4006895, PlaceboAlzheimer Disease, Healthy128Jul 2027≤ 346 d2026-06-04
A Study of LY4088044 in Healthy ParticipantsNCT07090785Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4088044, LY4088044, Placebo, PlaceboHealthy104Jul 2027≤ 346 d2026-08-07
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, PlaceboObesity, Overweight250Jul 2027≤ 346 d2026-04-17
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4065967, PlaceboDiabetic Peripheral Neuropathic Pain150Jul 2027≤ 346 d2026-07-07
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)NCT07545772Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of WeeksRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY3537031, PlaceboIrritable Bowel Syndrome, Constipation342Jul 2027≤ 346 d2026-08-06
A Study of LY4226695 in Healthy ParticipantsNCT07767487Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Not yet recruitingDrug: LY4226695, LY4226695, PlaceboHealthy148Jul 2027≤ 346 d2026-08-17
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3NCT05614739Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LOXO-435, Pembrolizumab, enfortumab vedotinUrinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms535Jun 2027≤ 315 d2026-06-18
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseNCT07483073Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)Randomized · Open-label · TreatmentPhase 2RecruitingDrug: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089Colitis, Ulcerative, Crohn Disease60Jun 2027≤ 315 d2026-08-06
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseNCT07483099Percentage of Participants with Crohn's Disease who Achieve Endoscopic ResponseRandomized · Open-label · TreatmentPhase 2RecruitingDrug: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)Crohn Disease60Jun 2027≤ 315 d2026-08-06
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)NCT07533006Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to (≤) 20Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4005130, PlaceboAlopecia Areata60Jun 2027≤ 315 d2026-08-06
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07765511Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Not yet recruitingDrug: Macupatide, Eloralintide, PlaceboObesity, Overweight60Jun 2027≤ 315 d2026-08-14
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerNCT05999994Number of Participants Allocated to Each ISARandomized · Open-label · TreatmentStudy Protocol ↗Phase 2RecruitingDrug: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, TemozolomideNeoplasms, Child, Adolescent105May 2027≤ 285 d2026-08-07
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)NCT06338995Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) SeverityRandomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: LY3650150, Placebo, Standard therapy for INCSChronic Rhinosinusitis With Nasal Polyps (CRSwNP)510May 2027≤ 285 d2026-08-06
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4052031Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer420May 2027≤ 285 d2026-08-05
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:NCT07186101Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4268989, Mirikizumab, LY4268989 PlaceboUlcerative Colitis252May 2027≤ 285 d2026-08-06
A Study of LY4005130 in Adult Participants With Non-Segmental VitiligoNCT07533019Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4005130, PlaceboVitiligo, Non-Segmental Vitiligo (NSV)66May 2027≤ 285 d2026-08-06
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Change from Baseline in Hemoglobin A1C (HbA1c)Open-label · TreatmentPhase 3Not yet recruitingDrug: OrforglipronDiabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, Peptide130May 2027≤ 285 d2026-06-23
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapyNon-randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, CarboplatinCarcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms540Apr 2027≤ 254 d2026-05-29
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainNCT05986292Number of Participants Who Were Allocated to Each ISARandomized · Double-masked · ScreeningStudy Protocol ↗Phase 2RecruitingDrug: LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, PlaceboOsteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain10,000Apr 2027≤ 254 d2026-06-23
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328Phase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199Randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4152199 - IVLymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell215Apr 2027≤ 254 d2026-07-10
A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersNCT07226843Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent ToxicitiesNon-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4584180, RituximabLymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma460Apr 2027≤ 254 d2026-08-06
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainNCT07641504Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4065967, PlaceboChronic Pain, Low Back Pain150Apr 2027≤ 254 d2026-08-19
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainNCT07641517Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4065967, PlaceboOsteoarthritis, Knee, Chronic Pain150Apr 2027≤ 254 d2026-08-19
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY4101174Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer490Mar 2027≤ 224 d2026-05-22
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Macupatide, Eloralintide, Macupatide Placebo, Eloralintide PlaceboObesity, Overweight, Diabetes Mellitus, Type 2200Mar 2027≤ 224 d2026-07-17
A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaNCT07269210Change from Baseline in TriglyceridesRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Solbinsiran, PlaceboSevere Hypertriglyceridemia60Mar 2027≤ 224 d2026-07-07
A Study of LY4515100 in Healthy ParticipantsNCT07339722Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and BRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, PlaceboHealthy123Mar 2027≤ 224 d2026-07-29
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.NCT07401862Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136Randomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY3841136Hepatic Insufficiency36Mar 2027≤ 224 d2026-06-04
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseNCT06297590Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY3954068, Placebo, Flortaucipir F18Alzheimer Disease48Feb 2027≤ 193 d2026-04-20
A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156Randomized · Open-label · TreatmentPhase 1RecruitingDrug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumabOvarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms495Feb 2027≤ 193 d2026-06-18
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNCT06413706Event Free Survival as Determined by Blinded Independent Review CommitteeRandomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Abemaciclib, TemozolomideGlioma45Feb 2027≤ 193 d2026-07-17
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Number of Participants Allocated to Each ISAOpen-label · ScreeningPhase 3RecruitingDrug: Orforglipron, PlaceboObesity, Overweight125Feb 2027≤ 193 d2026-07-20
A Study of LY3981314 in Healthy ParticipantsNCT07005284Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY3981314, PlaceboHealthy76Feb 2027≤ 193 d2026-05-19
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapseNCT07223840Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed SlipsRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: Brenipatide, PlaceboSmoking222Feb 2027≤ 193 d2026-08-06
A Study of Mirikizumab Solution (LY3074828) in Healthy ParticipantsNCT07446101Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3074828Randomized · Open-label · Basic sciencePhase 1RecruitingDrug: MirikizumabHealthy450Feb 2027≤ 193 d2026-05-14
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityNCT07476118Percent Change in Body WeightRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: Brenipatide · Other: PlaceboObesity, Overweight150Feb 2027≤ 193 d2026-07-16
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With CancerNCT07258836Number of Incidence of Adverse Events (AEs)Open-label · Basic sciencePhase 1RecruitingDrug: LY4214835Neoplasms, Healthy41Jan 2027≤ 165 d2026-08-06
A Study of LY4355756 in Healthy ParticipantsNCT07765498Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Not yet recruitingDrug: LY4355756, LY4355756, MidazolamHealthy123Jan 2027≤ 165 d2026-08-14
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, PaclitaxelBreast Cancer260Dec 2026≤ 134 d2026-08-07
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY3457263, PlaceboType 2 Diabetes240Dec 2026≤ 134 d2026-08-06
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesNCT06945406Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY4057996 SC, LY4057996 IV, Placebo SC, Placebo IV, Degludec SC, Lispro SC, Degludec IV, Pre-study basal insulin SCDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2124Dec 2026≤ 134 d2026-03-11
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With PlaceboRandomized · Double-masked · TreatmentPhase 1Active, not recruitingDrug: Retatrutide, Semaglutide, PlaceboDiabetes Mellitus, Insulin Sensitivity95Dec 2026≤ 134 d2026-07-16
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerNCT07169851Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINVRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background ChemotherapyNausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms204Dec 2026≤ 134 d2026-08-06
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07225556Number and Incidence of Serious Adverse Events (SAEs)Randomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY4167586, Placebo, LY4167586Overweight, Obesity84Dec 2026≤ 134 d2026-07-29
A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614Acetaminophen Area Under the Concentration Versus Time Curve (AUC)Randomized · Double-masked · TreatmentPhase 1Not yet recruitingDrug: Eloralintide, Placebo, AcetaminophenObesity, Overweight56Dec 2026≤ 134 d2026-07-31
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045Change from Baseline in Apnea-Hypopnea Index (AHI)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Orforglipron, PlaceboOSA, Overweight or Obesity600Nov 2026≤ 103 d2025-09-29
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, TirzepatideObesity800Nov 2026≤ 103 d2026-07-20
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Tirzepatide, PlaceboType 1 Diabetes, Obesity, Overweight905Nov 2026≤ 103 d2026-05-12
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Tirzepatide, PlaceboType 1 Diabetes, Obesity, Overweight465Nov 2026≤ 103 d2026-02-17
A Study of LY4064912 in Healthy Participants and With Overweight or ObesityNCT07152002Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY4064912, LY4064912, Placebo, PlaceboOverweight or Obesity, Healthy144Nov 2026≤ 103 d2026-08-18
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)Randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: LY3938577, DegludecDiabetes Mellitus, Type 2100Nov 2026≤ 103 d2026-07-13
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusNCT07299084Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test MealNon-randomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: TirzepatideDiabetes Mellitus, Type 2, Overweight, Obesity40Nov 2026≤ 103 d2026-05-19
A Study of LY4515100 in Participants With Pain Following Third Molar RemovalNCT07511816Change from Baseline in Self-Reported Pain IntensityRandomized · Double-masked · TreatmentPhase 2RecruitingDrug: LY4515100, PlaceboAcute Pain, Molar, Molar, Third, Surgery, Oral212Nov 2026≤ 103 d2026-05-01
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Baricitinib, TocilizumabSystemic Juvenile Idiopathic Arthritis58Oct 2026≤ 73 d2026-08-11
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Change from Baseline in Hemoglobin A1c (HbA1c) (%)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, PlaceboType 2 Diabetes320Oct 2026≤ 73 d2026-07-20
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136Non-randomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: LY3841136Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease28Oct 2026≤ 73 d2026-08-19
A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of EloralintideRandomized · Open-label · Basic sciencePhase 1Not yet recruitingDrug: EloralintideHealthy Volunteers58Oct 2026≤ 73 d2026-07-14
A Study of LY4268989 (MORF 057) in Healthy ParticipantsNCT07707375Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989Randomized · Open-label · Basic sciencePhase 1Not yet recruitingDrug: LY4268989Healthy50Oct 2026≤ 73 d2026-07-16
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI)Randomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: Tirzepatide, PlaceboOverweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D140Sep 2026≤ 42 d2026-05-08
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)NCT06280703Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Randomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY3938577, Placebo, Insulin Degludec, Insulin Lispro, LY3938577, Placebo, Insulin Degludec, Basal Insulin, Lispro Prandial InsulinHealthy, Type 1 Diabetes Mellitus118Sep 2026≤ 42 d2026-01-20
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)NCT06339008Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: LY3650150, Placebo, Standard therapy for INCSPerennial Allergic Rhinitis (PAR)450Sep 2026≤ 42 d2026-07-22
A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's DiseaseNCT07485153observationalPercentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study—Not yet recruitingDevice: Mobile EEG, Activity Monitor, Sleep StudyAlzheimer's Disease, Early Alzheimer's Disease, Memory Problems35Sep 2026≤ 42 d2026-03-20
A Study of Food Effect on Tersolisib (LY4064809) in Healthy ParticipantsNCT07662798Pharmacokinetics (PK): Maximum Concentration (Cmax) of TersolisibRandomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: Tersolisib · Other: High-fat Meal, Low-fat MealHealthy60Sep 2026≤ 42 d2026-08-19
A Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY3971297, Placebo, LY3971297 IVHealthy, Obesity, Hypertension225Aug 2026≤ 12 d2026-07-16
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Change from Baseline in Hemoglobin A1c (HbA1c) (%)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Retatrutide, SemaglutideDiabetes Mellitus, Type 21,250Aug 2026≤ 12 d2026-04-13
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach AcidNCT06916143Pharmacokinetic (PK): Area Under the Concentration Curve from 0 to Infinity (AUC0-∞) of LY4100511 (DC-853)Randomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: LY4100511, RabeprazoleHealthy Participants48Aug 2026≤ 12 d2026-07-16
A Study of LY3867070 in Healthy ParticipantsNCT07021547Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1RecruitingDrug: LY3867070, PlaceboHealthy196Aug 2026≤ 12 d2026-06-03
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentNCT07165002Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031Non-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY3537031Healthy, Hepatic Insufficiency32Aug 2026≤ 12 d2025-12-04
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's DiseaseNCT07254234observationalPercentage of Participants with the Same Results on the Blood Test and Retinal Scan—Not yet recruitingOther: Retinal scan, Blood testCognitive Dysfunction, Memory Disorders200Aug 2026≤ 12 d2025-11-28
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test MealRandomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: DulaglutideType 2 Diabetes Mellitus (T2DM)20Aug 2026≤ 12 d2026-04-16
A Study of Remternetug (LY3372993) in Healthy Chinese ParticipantsNCT07346495Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY3372993, PlaceboHealthy24Aug 2026≤ 12 d2026-06-17
A Study of Eltrekibart (LY3041658) in Healthy ParticipantsNCT07545590Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658Non-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY3041658, LY3041658Healthy60Aug 2026≤ 12 d2026-06-23
A Study of LY3537031 in Overweight, Obese, and Healthy ParticipantsNCT06606106Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Active, not recruitingDrug: LY3537031, PlaceboOverweight, Obesity302Jul 2026—2026-01-20
A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityNCT07232732Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: LY3549492Healthy, Obesity, Overweight120Jul 2026—2026-05-22
A Study of the Effects of Itraconazole on LY4395089 in Healthy ParticipantsNCT07592572Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from 0 to infinity (AUC[0-∞]) of LY4395089Non-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: LY4395089, Itraconazole, ItraconazoleHealthy14Jul 2026—2026-06-16
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: LY3841136, Tirzepatide, PlaceboObesity, Overweight3672026-07-01actual—2026-07-17
Zyprexa® Relprevv™ Patient Care ProgramNCT01088386observationalIncidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events—Enrolling by invitation—Schizophrenia4,000Jun 2026—2026-01-28
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667Percent Change from Baseline in Body Mass Index (BMI)Randomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Tirzepatide, PlaceboObesity, Overweight1602026-06-02actual—2026-06-29
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenNCT07006792Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from BaselineOpen-label · TreatmentPhase 4Active, not recruitingDrug: LebrikizumabAtopic Dermatitis2332026-05-14actual—2026-05-22
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisNCT06921759Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from BaselineRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Lebrikizumab, PlaceboAtopic Hand and Foot Dermatitis2212026-05-13actual—2026-06-25
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)NCT03519945Percentage of Participants in Clinical RemissionOpen-label · TreatmentPhase 3Active, not recruitingDrug: MirikizumabUlcerative Colitis1,0582026-03-04actual—2026-04-20
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightNCT06643728Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide PlaceboObesity, Overweight2522026-01-16actual—2026-05-26
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisNCT05559359Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from BaselineRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Lebrikizumab, Placebo, Topical Corticosteroid (TCS)Atopic Dermatitis, Eczema3772026-01-14actual—2026-07-30
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT04819100Event-Free Survival (EFS)Randomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: Selpercatinib, PlaceboCarcinoma, Non-Small-Cell Lung1522026-01-12actual—2026-03-04
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityNCT06037252Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: Tirzepatide, PlaceboType 2 Diabetes, Obesity4142026-01-08actual—2026-03-23
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineNCT04616326Change from Baseline in the Number of Monthly Migraine Headache DaysRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Galcanezumab, PlaceboChronic Migraine3122025-12-10actual—2026-02-27
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineNCT03432286Change from Baseline in the Number of Monthly Migraine Headache DaysRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Galcanezumab, PlaceboEpisodic Migraine5332025-11-14actual—2026-01-26
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesNCT05433584Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Open-label · TreatmentPhase 4Active, not recruitingDrug: Tirzepatide, Antihyperglycemic medicationType 2 Diabetes7802025-10-21actual—2025-12-12
A Study of LY3541860 in Adult Participants With Relapsing Multiple SclerosisNCT06220669Cumulative Number of New T1 Gadolinium-Enhancing (GdE) LesionsRandomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: LY3541860, PlaceboMultiple Sclerosis632025-10-18actual—2026-04-07
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06046729Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)Randomized · Double-masked · TreatmentPhase 2Active, not recruitingDrug: Eltrekibart, PlaceboHidradenitis Suppurativa3522025-09-30actual—2026-08-04
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisNCT06280716Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) (≥75% Reduction in EASI Score) for Mono CohortRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Placebo, Lebrikizumab, Topical CorticosteroidAtopic Dermatitis3012025-09-25actual—2025-10-15
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903results2026-08-14Percent Change From Baseline in Body Weight (Primary Treatment Period)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Orforglipron, PlaceboObesity, Overweight, Overweight or Obesity3,1272025-07-25actual—2026-08-14
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)NCT03157128results2026-04-16Phase 1: Maximum Tolerated Dose (MTD)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: LOXO-292Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor8572025-02-14actual—2026-04-16
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's SarcomaNCT05440786results2026-03-12Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian AnalysisRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Abemaciclib, Irinotecan, TemozolomideSarcoma, Ewing, Neoplasm Metastasis462025-01-15actual—2026-04-13
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseNCT04232553results2025-12-15Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: MirikizumabCrohn's Disease9962024-11-28actual—2026-08-11
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCNCT05611671results2025-12-15Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: MORF-057, PlaceboInflammatory Bowel Diseases, Colitis, Ulcerative2802024-11-28actual—2025-12-15
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsNCT03899792results2026-01-06Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: SelpercatinibMedullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma362024-11-08actual—2026-01-06
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentNCT05241834Phase 1 a: To determine the MTD/RP2D of LOXO-260: Dose limiting toxicity (DLT) rateNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LOXO-260Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms702024-09-17actual—2025-09-04
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308results2025-07-11Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Imlunestrant, Exemestane, Fulvestrant, AbemaciclibBreast Neoplasms, Neoplasm Metastasis8742024-06-24actual—2026-07-22
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486results2025-11-14Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Donanemab, Placebo, DexamethasoneAlzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders1,1752024-05-16actual—2026-06-18
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisNCT04527380results2025-06-05Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Ixekizumab, AdalimumabJuvenile Psoriatic Arthritis, Enthesitis Related Arthritis1012024-02-19actual—2026-08-12
A Study of LY3484356 in Chinese Participants With Advanced Breast CancerNCT05509790Pharmacokinetics (PK): Plasma Concentration of LY3484356Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3484356Breast Neoplasms172024-02-18actual—2026-04-13
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)NCT05288166results2025-06-27Radiographic Progression-Free Survival (rPFS) Assessed by InvestigatorRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for AbemaciclibProstatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 69252024-02-15actual—2026-07-01
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerNCT05169567results2025-02-27Progression-Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Abemaciclib, Fulvestrant, PlaceboBreast Neoplasm, Neoplasm Metastasis3682024-02-08actual—2026-01-16
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerNCT03706365results2025-03-06Radiographic Progression Free Survival (rPFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2/3Active, not recruitingDrug: Abemaciclib, Placebo, Abiraterone acetate, PrednisoneProstate Cancer3932024-01-02actual—2026-08-07
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentNCT04647526results2026-01-13Randomization Phase: Radiographic Progression-Free Survival (rPFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: [Lu-177]-PNT2002, Abiraterone, EnzalutamideMetastatic Castration-Resistant Prostate Cancer4552023-11-01actual—2026-01-13
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisNCT04088409results2024-08-13Part A: Percentage of Responders for Baricitinib at Week 24Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Baricitinib, AdalimumabUveitis302023-07-17actual—2026-04-24
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686Recommended Phase 2 Dose (RP2D)Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3410738, Gemcitabine, Cisplatin, DurvalumabCholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor2002023-07-17actual—2026-07-22
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsNCT04603001To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3410738, Venetoclax, AzacitidineAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)2602023-07-03actual—2026-07-22
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerNCT04194944results2024-06-20Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, PembrolizumabNon-Small Cell Lung Cancer2612023-05-01actual—2025-10-21
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511results2024-05-20Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Donanemab, PlaceboAlzheimer Disease1,7362023-04-14actual—2025-08-29
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaNCT04106219Number of Participants with Dose Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3295668 Erbumine, Topotecan, CyclophosphamideNeuroblastoma712022-04-13actual—2026-04-21
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationNCT04280081results2022-06-02Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: SelpercatinibSolid Tumor, Medullary Thyroid Cancer772021-03-25actual—2026-08-07
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadNCT02057133Number of Participants with One or More Drug-Related Adverse EventsNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapyBreast Neoplasms1982021-03-15actual—2026-01-26
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)NCT02951598observationalMean Economic Cost Associated with Amyloid Positive AD—Active, not recruitingDrug: Florbetapir F 18 PET ScanAlzheimer Disease, Mild Cognitive Impairment1,4002021-01-30actual—2025-10-24
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerNCT04188548Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent ToxicitiesRandomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), PertuzumabBreast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer3792020-06-29actual—2026-06-22
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997results2021-04-09Invasive Disease Free Survival (IDFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Abemaciclib, Standard Adjuvant Endocrine TherapyBreast Cancer5,6372020-03-16actual—2026-04-24
A Study of LY3200882 in Participants With Solid TumorsNCT02937272Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin · Radiation: Intensity Modulated RadiotherapySolid Tumor2232020-02-27actual—2026-04-03
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerNCT02779751Number of Participants with One or More Serious Adverse Event(s) (SAEs)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Abemaciclib, Pembrolizumab, AnastrozoleNon Small Cell Lung Cancer, Breast Cancer1002020-02-03actual—2026-01-26
A Study of Abemaciclib (LY2835219) in Participants With Breast CancerNCT02763566results2020-03-30Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Abemaciclib, Anastrozole, Letrozole, Placebo, FulvestrantBreast Cancer4632019-03-29actual—2026-02-05
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)NCT02411448results2020-03-04Part B: Progression Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol: Protocol I4T-MC-JVCY(f) ↗ · Study Protocol: Protocol Addendum I4T-MC-JVCY(9) ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Ramucirumab, Placebo, Erlotinib, Gefitinib, OsimertinibMetastatic Non-Small Cell Lung Cancer5452019-01-23actual—2026-01-16
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast CancerNCT02747004results2019-07-12Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Abemaciclib, Tamoxifen, Prophylactic LoperamideMetastatic Breast Cancer2342018-06-15actual—2026-02-06
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerNCT02711553results2021-02-26Progression Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IVBiliary Tract Cancer, Metastatic Cancer, Advanced Cancer3092018-02-16actual—2026-07-22
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerNCT02152631results2018-12-12Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol: Protocol ↗ · Study Protocol: Protocol (e) ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Abemaciclib, ErlotinibNon Small Cell Lung Cancer4532017-09-15actual—2026-02-06
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerNCT02107703results2018-03-13Progression-Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol: JPBL 05 Protocol_Redacted ↗ · Study Protocol: JPBL 05 Protocol (a)_Redacted ↗ · Study Protocol: JPBL 05 Protocol (b)_Redacted ↗ · Study Protocol: JPBL 05 Protocol (c)_Redacted ↗ · Study Protocol: JPBL 05 Protocol (d)_Redacted ↗ · Study Protocol: JPBL 05 Protocol (g)_Redacted ↗ · Statistical Analysis Plan: version 4 ↗ · Statistical Analysis Plan: Addendum for Overall Survival Analyses ↗Phase 3Active, not recruitingDrug: Abemaciclib, Fulvestrant, PlaceboBreast Neoplasms6692017-02-14actual—2025-10-21
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerNCT02246621results2018-03-23Progression Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol: JPBM Protocol (a) ↗ · Study Protocol: JPBM Protocol (b) ↗ · Study Protocol: JPBM Protocol ↗ · Statistical Analysis Plan: SAP V5 Addendum ↗ · Statistical Analysis Plan: SAP V5 ↗Phase 3Active, not recruitingDrug: Abemaciclib, Anastrozole, Letrozole, PlaceboBreast Cancer4932017-01-31actual—2026-02-03
A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsNCT01594723Percentage of Participants with an Objective Response (Objective Response Rate)Open-label · TreatmentPhase 2Active, not recruitingDrug: 120 mg LY2784544Neoplasms, Hematologic1102015-03-20actual—2026-06-23
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesNCT06945419Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4086940, Placebo, LY4086940Healthy, Overweight, Obesity, Type 2 Diabetes2192026-08-05actual—2026-08-19
A Study of LY4065967 in Healthy ParticipantsNCT07607483Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 CapsuleHealthy362026-07-27actual—2026-08-19
A Study of How the Body Absorbs LY3537031NCT07202871Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3537031Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537031, LY3537031Healthy472026-07-17actual—2026-07-23
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionNCT06916078Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LepodisiranNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LepodisiranLiver Dysfunction, Healthy302026-07-13actual—2026-08-19
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Retatrutide, PlaceboType 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea1,1522026-06-16actual—2026-07-30
A Study of [14C]-LY4064809 in Healthy ParticipantsNCT07519525To determine the absolute bioavailability (F) of LY4064809 following administration of a single oral dose compared to an intravenous reference dose in healthy participants.Open-label · Basic sciencePhase 1CompletedDrug: LY4064809, [14C]-LY4064809Healthy72026-05-26actual—2026-06-08
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT05395481Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3849891, PlaceboMetabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)1152026-05-12actual—2026-06-24
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL)Randomized · Double-masked · TreatmentPhase 1CompletedDrug: Retatrutide, PlaceboType 2 Diabetes Mellitus802026-05-04actual—2026-06-18
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisNCT05784246Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical RespondersNon-randomized · Open-label · TreatmentPhase 3CompletedDrug: Mirikizumab IV, Mirikizumab SCUlcerative Colitis632026-05-01actual—2026-06-03
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseNCT06538116Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)Randomized · Double-masked · TreatmentPhase 2CompletedDrug: Mevidalen, PlaceboAlzheimer Disease3042026-05-01actual—2026-06-18
A Study of LY4005130 in Healthy ParticipantsNCT06690996Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4005130, LY4005130, Placebo, PlaceboHealthy1102026-04-28actual—2026-06-23
A Study of Olomorasib (LY3537982) in Healthy ParticipantsNCT07439250Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of OlomorasibOpen-label · Basic sciencePhase 1CompletedDrug: Olomorasib, FluconazoleHealthy152026-04-17actual—2026-05-19
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Retatrutide, PlaceboObesity, Cardiovascular Diseases1,9462026-04-16actual—2026-07-30
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal ImpairmentNCT07165015Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537031Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)312026-04-16actual—2026-04-24
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During RamadanNCT06635057Change from Baseline in Hemoglobin A1c (HbA1c)Open-label · TreatmentPhase 4CompletedDrug: TirzepatideType 2 Diabetes1662026-04-15actual—2026-05-22
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney FunctionNCT07137689Pharmacokinetics: Maximum Concentration (Cmax) of LY3537982Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537982Renal Insufficiency322026-04-10actual—2026-04-23
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Retatrutide, PlaceboObesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea2,3352026-04-06actual—2026-06-03
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy ParticipantsNCT06977880Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)Randomized · Single-masked · Basic sciencePhase 1CompletedDrug: LY4292009, PlaceboHealthy802026-03-20actual—2026-04-17
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback MethodRandomized · Double-masked · OtherPhase 2CompletedDrug: Mazdutide, PlaceboAlcohol Use Disorder3082026-03-19actual—2026-07-16
A Study of LY4064809 in Healthy Adult ParticipantsNCT07339735Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4064809 Test Formulation, LY4064809 Reference FormulationHealthy Participants242026-03-19actual—2026-04-20
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]Randomized · Open-label · TreatmentPhase 3CompletedDrug: Orforglipron, Insulin GlargineType 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease2,7492026-03-16actual—2026-04-17
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese ParticipantsNCT06869018Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3549492, PlaceboHealthy, Type 2 Diabetes Mellitus (T2D)922026-03-02actual—2026-03-20
A Study of LY3985863 in Healthy ParticipantsNCT07030127Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3985863, PlaceboHealthy242026-02-24actual—2026-03-11
A Study of LY4060874 in Healthy ParticipantsNCT06709820Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4060874, LY4060874, Placebo, PlaceboHealthy Participants1212026-02-20actual—2026-04-03
A Study of LY4268989 (MORF-057) in Healthy ParticipantsNCT06964776Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4268989, Placebo, Midazolam, MidazolamHealthy1442026-02-17actual—2026-03-27
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes MellitusNCT07073170Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3549492, PlaceboType 2 Diabetes362026-01-27actual—2026-03-03
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051Percent Change from Baseline in Visceral Adipose Tissue (VAT)Randomized · Double-masked · TreatmentPhase 1CompletedDrug: Orforglipron, PlaceboObesity, Overweight1202026-01-26actual—2026-02-25
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660Change from Baseline in Hemoglobin A1c (HbA1c) (%)Randomized · Double-masked · TreatmentPhase 3CompletedDrug: Retatrutide, PlaceboDiabetes Type 25372026-01-22actual—2026-03-05
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06047548Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss PeriodRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Tirzepatide, PlaceboOverweight, Obesity4412026-01-20actual—2026-03-25
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityNCT06916065Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and TirzepatideNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: Eloralintide and Tirzepatide, EloralintideOverweight, Obesity1882026-01-19actual—2026-01-30
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyNCT06568042Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)Randomized · Double-masked · TreatmentPhase 2CompletedDrug: LY3848575, PlaceboNeuropathic Pain, Distal Sensory Polyneuropathy5582026-01-12actual—2026-07-10
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight ReductionRandomized · Open-label · TreatmentPhase 3CompletedDrug: Ixekizumab, TirzepatidePsoriasis, Obesity2812026-01-08actual—2026-06-17
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06683508Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2CompletedDrug: LY3549492, PlaceboObesity, Overweight2882026-01-07actual—2026-05-13
A Study of Olomorasib (LY3537982) in Healthy Japanese ParticipantsNCT07124013Pharmacokinetics (PK): Maximum Concentration (Cmax) of OlomorasibRandomized · Open-label · Basic sciencePhase 1CompletedDrug: OlomorasibHealthy1912026-01-05actual—2026-01-16
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes MellitusNCT06362265Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3209590Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3209590Type 2 Diabetes Mellitus152026-01-02actual—2026-03-24
A Study of LY4064809 in Healthy Adult Chinese ParticipantsNCT07247357Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809Open-label · Basic sciencePhase 1CompletedDrug: LY4064809Healthy102025-12-16actual—2026-01-16
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityNCT06373146Mean Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2CompletedDrug: Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-PlaceboObesity3922025-12-15actual—2026-05-06
A Study of Remternetug (LY3372993) in Healthy ParticipantsNCT07056309Pharmacokinetic (PK): Maximum Concentration (Cmax) of RemternetugRandomized · Open-label · Basic sciencePhase 1CompletedDrug: Remternetug (Test), Remternetug (Reference)Healthy722025-12-15actual—2026-01-23
A Study of LY3532226 in Participants With ObesityNCT06557356Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3532226, PlaceboObesity1322025-12-12actual—2026-01-20
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisNCT05848258Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)Randomized · Double-masked · TreatmentPhase 2CompletedDrug: LY3871801, PlaceboRheumatoid Arthritis1642025-12-08actual—2026-05-22
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineNCT04396574results2026-06-25Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Terminatedsponsor's stated reason: Study terminated due to strategic business decisionDrug: LasmiditanMigraine5582025-12-04actual—2026-06-25
A Study of LY3841136 in Japanese Participants With Obesity or OverweightNCT06297616Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22Randomized · Double-masked · TreatmentPhase 1CompletedDrug: LY3841136, LY3841136-Placebo, Tirzepatide, Tirzepatide-PlaceboObesity, Overweight1282025-11-21actual—2026-01-16
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5Randomized · Double-masked · TreatmentPhase 3CompletedDrug: Orforglipron, PlaceboObesity, Overweight3762025-11-21actual—2026-06-04
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight ReductionRandomized · Open-label · TreatmentPhase 3CompletedDrug: Ixekizumab, TirzepatidePsoriatic Arthritis, Obesity2792025-11-18actual—2026-05-13
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale ScoreRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Retatrutide, PlaceboObesity, Overweight, Osteo Arthritis Knee4452025-11-14actual—2026-01-21
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineNCT04396236Percentage of Participants with Pain Freedom (High Dose)Randomized · Double-masked · TreatmentPhase 3Terminatedsponsor's stated reason: Study terminated due to strategic business decisionDrug: Lasmiditan, PlaceboMigraine8512025-11-12actual—2026-03-10
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid ArthritisNCT06859294Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP)Open-label · TreatmentPhase 2Terminatedsponsor's stated reason: The interim analysis data failed to demonstrate the intended treatment effect.Drug: LY3541860Rheumatoid Arthritis352025-11-10actual—2026-06-17
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsNCT07044271Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of OlomorasibRandomized · Open-label · Basic sciencePhase 1CompletedDrug: OlomorasibHealthy1202025-11-08actual—2026-05-29
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Change from Baseline in Glomerular Filtration Rate (mGFR)Randomized · Double-masked · TreatmentPhase 2CompletedDrug: Retatrutide, PlaceboOverweight or Obesity, CKD, Type 2 Diabetes1462025-10-01actual—2025-11-25
A Study of LY3841136 in Overweight and Obese ParticipantsNCT06345066Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: Tirzepatide, LY3841136, PlaceboObesity, Overweight962025-09-29actual—2025-10-15
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108Change from Baseline in Hemoglobin A1c: (HbA1c)Randomized · Open-label · TreatmentPhase 3CompletedDrug: Orforglipron, DapagliflozinType 2 Diabetes9622025-09-26actual—2025-10-20
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsNCT06890611Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test MaterialRandomized · Open-label · Basic sciencePhase 1CompletedDrug: Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide CoformulationHealthy1252025-09-26actual—2025-10-09
A Single and Multiple Ascending Dose Study of LY3876602 in Healthy ParticipantsNCT06007638Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3876602, PlaceboHealthy742025-09-20actual—2025-09-24
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentPhase 3CompletedDrug: Orforglipron, PlaceboType 2 Diabetes5462025-09-15actual—2025-10-20
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightNCT06916091Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: Eloralintide, PlaceboObesity, Overweight302025-09-09actual—2025-11-19
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in IndiaNCT06370715Percentage of Participants with at least 1 Episode of HypoglycemiaOpen-label · TreatmentPhase 4CompletedDrug: Insulin Lispro-aabc, Insulin GlargineDiabetes Mellitus, Type 21502025-09-02actual—2025-10-16
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult ParticipantsNCT06991179Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4064809Healthy362025-09-02actual—2025-09-23
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)Randomized · Double-masked · TreatmentPhase 1CompletedDrug: LY3437943 · Other: PlaceboObesity852025-08-26actual—2025-09-23
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsNCT06719128Pharmacokinetics (PK): Maximum observed concentration (Cmax) of OlomorasibNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: OlomorasibHepatic Insufficiency, Healthy462025-08-25actual—2025-09-22
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221Change from Baseline in Hemoglobin A1c (HbA1c)Randomized · Open-label · TreatmentPhase 3CompletedDrug: Orforglipron, SemaglutideType 2 Diabetes1,6982025-08-22actual—2025-09-22
A Study of [14C]-LY4065967 in Healthy ParticipantsNCT07039045Part 1: Percentage of Total Radioactive Dose in Urine and Fecal ExcretionNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4065967 · Radiation: [14C]-LY4065967 Oral, [14C]-LY4065967 IVHealthy162025-08-16actual—2025-09-09
A Study of LY3549492 in Healthy Weight Adult ParticipantsNCT07085468Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 2Terminatedsponsor's stated reason: Study terminated for strategic business reasonsDrug: LY3549492, PlaceboHealthy12025-08-14actual—2025-08-29
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620Mean Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Orforglipron, PlaceboObesity, Overweight, Type 2 Diabetes1,6132025-08-08actual—2025-09-18
A First-In-Human Study of LY3985297 in Healthy ParticipantsNCT06395012Number of participants with one or more Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3985297, PlaceboHealthy1402025-08-06actual—2025-09-11
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesNCT07030868Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2Terminatedsponsor's stated reason: Study terminated for strategic business reasonsDrug: LY6249492, PlaceboObesity, Overweight, Type 2 Diabetes12025-07-29actual—2025-08-29
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT06602219results2026-08-18Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY4100511, PlaceboPlaque Psoriasis2222025-07-24actual—2026-08-18
A Study of LY3537982 in Chinese Participants With Advanced Solid TumorsNCT06235983Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3537982Open-label · TreatmentPhase 1CompletedDrug: LY3537982Advanced Solid Tumors122025-07-02actual—2026-05-29
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380results2026-07-20Percent Change From Baseline in Body Weight at Week 72Randomized · Double-masked · TreatmentStudy Protocol: Amendment (b) ↗ · Study Protocol: Errata to Amendment (b) ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Orforglipron, PlaceboObesity2382025-06-19actual—2026-07-20
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433results2026-07-08Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, DulaglutideType 2 Diabetes Mellitus13,2992025-06-12actual—2026-07-08
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic PainNCT06074562results2026-07-30Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Bayesian Model Averaging (BMA) Dose-response ModelRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: Mazisotine, PlaceboDiabetic Peripheral Neuropathy4042025-06-11actual—2026-07-30
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesNCT06901349Percent Change from Baseline in Body WeightRandomized · Double-masked · TreatmentPhase 2Withdrawnsponsor's stated reason: Study terminated for strategic business reasonsDrug: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide PlaceboObesity, Overweight02025-06-10actual—2025-09-24
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsNCT06692348Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State)Randomized · Open-label · Basic sciencePhase 1CompletedDrug: OrforglipronHealthy862025-06-09actual—2025-06-24
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004results2026-06-30Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: OrforglipronType 2 Diabetes4012025-06-05actual—2026-06-30
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980results2026-07-17Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: OrforglipronHealthy, Obese, Overweight, Obesity5332025-06-02actual—2026-07-17
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523results2026-06-24Percent Change From Baseline in Body Weight at Week 48Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: Eloralintide, PlaceboObesity, Overweight2632025-05-30actual—2026-06-24
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964results2026-06-24Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: Baricitinib, TNF InhibitorRheumatoid Arthritis2,6592025-05-28actual—2026-06-24
A First-In-Human Study of LY3839840 in Healthy ParticipantsNCT06153355Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3839840, Placebo, MidazolamHealthy1402025-05-22actual—2025-06-06
A Study of Baricitinib in Participants With Rheumatoid ArthritisNCT04086745results2026-07-10Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: Baricitinib, TNF InhibitorRheumatoid Arthritis1,0502025-05-19actual—2026-07-10
A Study of LY4064809 [14C]-STX-478 in Healthy Male ParticipantsNCT06901336Percentage of the Total Radioactive Dose in Urinary, Fecal, and Urinary and Fecal Combined ExcretionOpen-label · Basic sciencePhase 1CompletedDrug: [14C]-STX-478Healthy82025-05-06actual—2025-05-25
A Study of LY3873862 in Healthy ParticipantsNCT05492201Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3873862, PlaceboHealthy842025-04-29actual—2025-05-11
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of MetoprololOpen-label · Basic sciencePhase 1CompletedDrug: Retatrutide, MetoprololHealthy302025-04-15actual—2025-06-05
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940results2026-04-22Change From Baseline in HbA1cRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Orforglipron, PlaceboType 2 Diabetes5592025-04-03actual—2026-04-22
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT06176768results2025-10-15Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3972406, PlaceboPlaque Psoriasis332025-04-01actual—2025-10-15
A Study of LY4065967 in Healthy Japanese ParticipantsNCT06594159Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4065967, Placebo, RosuvastatinHealthy592025-03-11actual—2025-04-03
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943Healthy, Hepatic Insufficiency432025-03-02actual—2025-04-18
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)NCT06007651results2026-04-13Part A: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1Terminatedsponsor's stated reason: Participants were not dosed in Part B as per the protocol.Drug: LY3885125, PlaceboDyslipidemias, Non-Alcoholic Fatty Liver Disease492025-02-12actual—2026-04-13
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsNCT06704763results2026-05-26Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of OrforglipronOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Orforglipron, Midazolam, QuinidineHealthy272025-02-05actual—2026-05-26
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)NCT05592275results2026-02-05Change From Baseline in Left Atrial Reservoir Strain (LARS) at Week 26Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Terminatedsponsor's stated reason: An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population.Drug: LY3540378, PlaceboHeart Failure, Heart Failure With Preserved Ejection Fraction3322025-01-22actual—2026-02-05
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807results2026-04-21Percent Change From Baseline in Body Weight at Week 32Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: Mazdutide, PlaceboObesity, Overweight and Obesity1792025-01-22actual—2026-04-21
A Study of Tirzepatide (LY3298176) in Pediatric Participants With ObesityNCT05696847results2025-08-26Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Tirzepatide, PlaceboObesity282025-01-16actual—2025-08-26
A Study of [14C]-LY3866288 in Healthy ParticipantsNCT06644378Part A, Fraction of [14C]-LY3866288 Dose Excreted in Urine (Feur) Expressed as a Percentage of the Total Radioactive Dose AdministeredOpen-label · Basic sciencePhase 1CompletedDrug: [14C]-LY3866288, LY3866288, [14C]-LY3866288Healthy152025-01-03actual—2025-01-22
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy ParticipantsNCT06503679Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Midazolam, in the absence or presence of steady-state LY4100511Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, RosuvastatinHealthy492024-12-31actual—2025-01-24
A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male ParticipantsNCT06627088Part A: Total Radioactivity Recovery and Excretion (TRA)Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4100511 (DC-853), [14C]-LY4100511 (DC-853) Administered oral dose, LY4100511 (DC-853), [14C]-LY4100511 (DC-853)Healthy242024-12-31actual—2025-01-24
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney DiseaseNCT06598631Percent Change from Baseline of Urine Albumin-Creatinine Ratio (UACR)Randomized · Double-masked · TreatmentPhase 2Withdrawnsponsor's stated reason: Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.Drug: Volenrelaxin, PlaceboChronic Kidney Disease02024-12-30actual—2025-10-02
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy ParticipantsNCT06475729results2025-12-30Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of MirikizumabRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Citrate-Free MirikizumabHealthy4982024-12-27actual—2025-12-30
A Study of LY3866288 in Healthy ParticipantsNCT06641037Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3866288Healthy152024-12-02actual—2025-04-01
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy ParticipantsNCT04451408Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Triple-masked · Basic sciencePhase 1CompletedDrug: LY3372993, PlaceboAlzheimer Disease, Healthy1392024-11-18actual—2025-03-28
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032results2026-05-27Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970Healthy, Hepatic Insufficiency292024-11-18actual—2026-05-27
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesNCT05822830results2025-11-26Percent Change From Baseline in Body WeightRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, SemaglutideObesity, Overweight7512024-11-13actual—2025-11-26
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic DermatitisNCT05911841results2025-12-02Percentage of Biologic and Small Molecule Naive Participants Achieving Eczema Area and Severity Index (EASI) 75 (≥75% Reduction in EASI Score) at Week 16Randomized · Double-masked · TreatmentStudy Protocol: IMMB(b) Protocol ↗ · Study Protocol: FR01(c) Protocol ↗ · Statistical Analysis Plan: FR01 Statistical Analysis Plan (Version 3) ↗ · Statistical Analysis Plan: IMMB Statistical Analysis Plan (Version 1) ↗Phase 2Terminatedsponsor's stated reason: The decision to terminate the study was due to efficacy/effectiveness reasons.Drug: LY3454738, PlaceboAtopic Dermatitis2342024-10-10actual—2025-12-02
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)NCT05963022results2025-10-21Change From Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, PlaceboType 2 Diabetes2062024-10-09actual—2025-10-21
A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian ParticipantsNCT06311656Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4100511 (DC-853), LY4100511 (DC-853), LY4100511 (DC-853), LY4100511 (DC-853), PlaceboHealthy692024-10-04actual—2025-02-24
A Study of LY8888AX in Participants Using a Connected Insulin Management PlatformNCT05893797results2025-11-10Number of Missed Bolus Doses (MBDs) Per WeekOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Not applicableCompletedDrug: Insulin Lispro · Device: Tempo Smart Button, Dexcom G6 CGM, Glooko Research Mobile App (RMA)Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin362024-09-16actual—2025-11-10
A Study of Subcutaneous Injection in Healthy ParticipantsNCT06516913Usability Assessment of Subcutaneous Injections Using a Syringe Pump Across Multiple Delivery ParametersRandomized · Single-masked · Device feasibilityNot applicableCompletedDevice: Harvard Apparatus syringe pumpHealthy322024-09-07actual—2025-08-27
A Study of LY3473329 in Participants With Impaired and Normal Renal FunctionNCT05778864Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3473329Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3473329Renal Insufficiency472024-09-06actual—2024-10-28
A Study of Baricitinib (LY3009104) in Children With COVID-19NCT05074420results2026-08-11Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of BaricitinibOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Terminatedsponsor's stated reason: Study terminated due to an inability to enroll participants.Drug: BaricitinibCovid19, Corona Virus Infection62024-09-05actual—2026-08-11
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese ParticipantsNCT06243198results2025-09-12Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Lebrikizumab, PlaceboHealthy242024-09-03actual—2025-09-12
A Study of LY3541105 in Healthy and Overweight ParticipantsNCT05380323Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3541105, PlaceboOverweight, Healthy2062024-08-27actual—2025-06-27
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisNCT05767021results2025-09-30Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Mirikizumab, MirikizumabUlcerative Colitis, Ulcerative Colitis Chronic1722024-08-09actual—2026-06-10
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in IndiaNCT05855967results2025-08-22Number of Participants Reporting Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) and AEs of Special Interests (AESIs) From Week 0 to Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: IxekizumabPlaque Psoriasis, Psoriatic Arthritis2502024-08-08actual—2025-08-22
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothNCT05260021results2025-09-26Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide Dose 1, Tirzepatide Dose 2, PlaceboType2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease992024-07-30actual—2025-09-26
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095results2026-07-17Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970, PlaceboOverweight, Obesity242024-07-29actual—2026-07-17
A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943, LY3437943Healthy852024-07-25actual—2024-10-01
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsNCT06370728results2026-07-17Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of OrforglipronOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Orforglipron, CarbamazepineHealthy302024-07-23actual—2026-07-17
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)NCT04392154results2025-08-03Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse EventsNon-randomized · Double-masked · TreatmentStudy Protocol: Study Protocol ↗ · Study Protocol: Study Protocol Addendum ↗ · Statistical Analysis Plan ↗Phase 3CompletedBiological: LebrikizumabAtopic Dermatitis1,1532024-07-19actual—2025-11-05
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)NCT05662332results2025-08-06Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Insulin Efsitora Alfa, Insulin GlargineType 2 Diabetes, T2D7952024-07-19actual—2025-08-06
A Multiple Dose Study of LY3209590 in Participants With Type 2 DiabetesNCT06169982Pharmacokinetics (PK): Area under the concentration curve during one dosing interval at steady state (AUCss) of LY3209590Open-label · Basic sciencePhase 1CompletedDrug: LY3209590Diabetes Mellitus, Type 2562024-07-18actual—2024-09-04
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039results2025-08-03Change From Baseline in HbA1cRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: Tirzepatide, DulaglutideType 2 Diabetes2822024-07-15actual—2025-08-03
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl EstradiolNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943, Ethinyl Estradiol, DrospirenoneOverweight462024-07-11actual—2024-07-26
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622results2026-05-22Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium BicarbonateHealthy, Obese, Overweight502024-07-10actual—2026-05-22
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseNCT05063539results2025-07-28Change From Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3372689, LY3372689, PlaceboAlzheimer Disease3272024-07-09actual—2026-06-12
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557results2025-08-20Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide · Other: PlaceboObesity, Heart Failure With Preserved Ejection Fraction (HFpEF)7312024-07-02actual—2025-08-20
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 DiabetesNCT05691712results2025-08-08Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, PlaceboDiabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases2572024-07-01actual—2025-08-08
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes MellitusNCT06132126Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3938577, Placebo, Insulin degludecHealthy, Type 2 Diabetes Mellitus662024-06-28actual—2024-07-24
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerNCT04752332results2025-07-15Invasive Disease Free Survival (IDFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Terminatedsponsor's stated reason: Study is terminated due to inability to enroll study participantsDrug: Abemaciclib, Standard Adjuvant ET, PlaceboBreast Neoplasms1112024-06-26actual—2025-07-15
A Study to Assess LY4100511 (DC-853) in Healthy Adult ParticipantsNCT06345794Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY4100511 (DC-853), Itraconazole, Fluconazole, CarbamazepineHealthy502024-06-18actual—2025-04-27
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell TumorNCT04145349results2025-07-20Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2CompletedDrug: Ramucirumab, Cyclophosphamide, VinorelbineDesmoplastic Small Round Cell Tumor302024-06-14actual—2026-08-07
Lebrikizumab Pen Ease of Use in Participants With Atopic DermatitisNCT06444165results2025-07-29Percentage of Participants Who Responded Agree or Strongly Agree to the 'Overall Ease of Use' Question Using the Modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Lebrikizumab PenAtopic Dermatitis552024-06-10actual—2025-07-29
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseNCT05616013results2025-07-18Change From Baseline in Body Weight at Week 48Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedBiological: Bimagrumab · Drug: Semaglutide · Other: PlaceboObesity, Obese, Overweight or Obesity5072024-05-16actual—2026-07-08
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal InsulinNCT05275400results2025-06-03Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Insulin Efsitora Alfa, Insulin DegludecType 2 Diabetes9862024-05-15actual—2025-06-03
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection FractionNCT04840914Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3461767, PlaceboChronic Heart Failure With Reduced Ejection Fraction442024-05-09actual—2024-05-30
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744results2025-06-24Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Insulin Efsitora Alfa, Insulin DegludecType 1 Diabetes, Diabetes6922024-05-07actual—2025-06-24
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of ColorNCT05372419results2025-06-11Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: LebrikizumabAtopic Dermatitis902024-05-03actual—2026-03-09
A Relative Bioavailability Study of LY3454738 in Healthy ParticipantsNCT06173895Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3454738Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3454738Healthy302024-05-02actual—2024-05-30
A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male ParticipantsNCT06342596Part 1: Urinary Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose AdministeredOpen-label · Basic sciencePhase 1CompletedDrug: [14C]-LY3473329, [14C]-LY3473329, LY3473329Healthy162024-05-01actual—2024-05-30
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)NCT05463731Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus PlaceboRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Remternetug (IV), Remternetug (SC), PlaceboAlzheimer's Disease1,6672024-04-24actual—2026-05-22
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT05327595Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · TreatmentPhase 1CompletedDrug: LY3549492, Placebo, Atorvastatin, MidazolamDiabetes Mellitus, Type 2802024-04-22actual—2024-05-30
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138results2026-06-09Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970Renal Insufficiency, Healthy242024-04-11actual—2026-06-09
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First TimeNCT05362058results2025-05-16Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Insulin Efsitora Alfa, Insulin DegludecDiabetes, Type 2 Diabetes9282024-04-10actual—2025-05-16
A Study of LY3872386 in Healthy Participants and Participants With Atopic DermatitisNCT06119529results2025-10-03Part A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1Terminatedsponsor's stated reason: Based on emerging nonclinical data, the study was terminated.Drug: LY3872386, Prednisone, PlaceboHealthy, Atopic Dermatitis182024-04-08actual—2025-10-03
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy ParticipantsNCT06111521Part 1: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3537982Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537982, Digoxin, Rosuvastatin, Midazolam, MidazolamHealthy352024-04-01actual—2024-11-08
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisNCT05896527results2025-04-04Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: DC-806 · Other: PlaceboPlaque Psoriasis2292024-03-25actual—2025-04-04
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaNCT04238819results2025-08-06Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2CompletedDrug: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSFRelapsed Solid Tumor, Refractory Solid Tumor472024-03-15actual—2026-03-02
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsNCT05563246results2025-03-25Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) AssayRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3473329, PlaceboLipoprotein Disorder2332024-03-14actual—2025-03-25
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisNCT04469062Percentage of Participants in Histologic RemissionRandomized · Double-masked · TreatmentPhase 3Withdrawnsponsor's stated reason: The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.Drug: Mirikizumab IV, Mirikizumab SC, Vedolizumab IV, Placebo IV, Placebo SCUlcerative Colitis02024-03-13—2021-05-06
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004results2025-04-30Change From Baseline in Apnea-Hypopnea Index (AHI)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, PlaceboObstructive Sleep Apnea, Obesity4692024-03-12actual—2025-04-30
A Study of Tirzepatide (LY3298176) in Healthy Lactating FemalesNCT05978713results2025-04-27Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: TirzepatideHealthy112024-03-12actual—2025-04-27
A Study of LY3561774 in Participants With Mixed DyslipidemiaNCT05256654results2025-03-17Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3561774, PlaceboDyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia2052024-03-04actual—2025-03-17
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionNCT05440344results2025-11-12Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of ImlunestrantNon-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: ImlunestrantHepatic Insufficiency, Healthy272024-02-28actual—2025-11-12
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)NCT04640077results2025-06-13Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) AssessmentsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedOther: No Intervention · Drug: donanemabAlzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment952024-02-27actual—2025-06-13
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily InjectionsNCT05462756results2025-04-27Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)Type 2 Diabetes, Type 2 Diabetes Treated With Insulin7302024-02-27actual—2025-04-27
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentNCT05999968Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationOpen-label · TreatmentPhase 1Terminatedsponsor's stated reason: The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.Drug: Abemaciclib, Darolutamide, LHRH agonist/antagonistProstatic Neoplasms102024-02-23actual—2026-06-26
A Study of LY3532226 in Participants With Type 1 Diabetes MellitusNCT05887999Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemiaRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3532226, PlaceboDiabetes Mellitus, Type 1302024-02-21actual—2024-03-26
A Study of LY3848575 in Healthy ParticipantsNCT05727072Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3848575, LY3848575, Placebo, PlaceboHealthy642024-02-19actual—2024-04-04
A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy ParticipantsNCT06194500Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part ANon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [14C]-LY3549492, LY3549492, [14C]-LY3549492Healthy Male182024-02-15actual—2024-03-28
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943 · Device: Test, ReferenceHealthy572024-02-08actual—2024-03-29
A Study of LY3841136 in Healthy and Overweight ParticipantsNCT05295940Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3841136, PlaceboObesity, Healthy1482024-01-25actual—2024-04-01
A Study of LY3844583 in Healthy Participants and Participants With Atopic DermatitisNCT05486208Number of Participants with One or More Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Terminatedsponsor's stated reason: Study terminated due to lack of efficacy signal in atopic dermatitis participants.Drug: LY3844583, PlaceboHealthy, Dermatitis, Atopic1022024-01-20actual—2024-05-10
A Study to Compare Two Formulations of LY3209590 in Healthy ParticipantsNCT05914688Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the Last Time Point (AUC[0-tlast]) of LY3209590Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3209590 (Formulation 1), LY3209590 (Formulation 2)Healthy672024-01-18actual—2024-04-23
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaNCT05659537results2025-02-05Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and DeathsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: DulaglutideDiabetes Mellitus, Type 22122024-01-16actual—2025-02-20
A Study of LY3532226 in Participants With Type 2 Diabetes MellitusNCT05407961Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3532226, Placebo, DulaglutideDiabetes Mellitus, Type 2902024-01-12actual—2024-03-29
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabNCT05369403results2025-03-19Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: LebrikizumabAtopic Dermatitis862024-01-11actual—2026-02-25
A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy ParticipantsNCT05959109Pharmacokinetics (PK): Maximum Concentration (Cmax) of PeresolimabNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: PeresolimabHealthy572024-01-11actual—2024-01-29
A Study of LY3875383 in Healthy Participants and Participants With HypertriglyceridemiaNCT05609825Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Terminatedsponsor's stated reason: The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development.Drug: LY3875383, PlaceboHypertriglyceridemia412024-01-10actual—2025-06-04
A Study of LY3819469 in Participants With Impaired and Normal Renal FunctionNCT05841277Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to last time point (AUC0-tlast) of LY3819469Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3819469Renal Insufficiency, Healthy262024-01-09actual—2024-03-29
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482results2026-05-27Pharmacokinetics (PK): Absolute Bioavailability of LY3502970Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970, [14C]-LY3502970Healthy102024-01-05actual—2026-05-27
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus ErythematosusNCT05123586results2025-01-20Percentage of Participants With Arthritis and/or Rash at Baseline Who Achieve Remission of Arthritis and/or RashRandomized · Double-masked · TreatmentStudy Protocol: Protocol ISA J1V-MC-BT01 (a) ↗ · Study Protocol: Master Protocol J1V-MC-IMMA ↗ · Statistical Analysis Plan: Statistical Analysis Plan J1V-MC-BT01 Version 3 ↗ · Statistical Analysis Plan: Statistical Analysis Plan J1V-MC-IMMA Version 2 ↗Phase 2Terminatedsponsor's stated reason: Study terminated due to lack of efficacyDrug: LY3361237, PlaceboSystemic Lupus Erythematosus852023-12-29actual—2025-01-20
A Study of LY3541860 in Healthy Japanese and Non-Japanese ParticipantsNCT05042310Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3541860, PlaceboHealthy942023-12-27actual—2024-04-05
A Study to Evaluate the Effect of Food on LOXO-783 in Healthy ParticipantsNCT06028425Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LOXO-783Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LOXO-783Healthy422023-12-23actual—2024-07-22
A Study of [14C]-LOXO-783 in Healthy Adult ParticipantsNCT06102512Pharmacokinetics (PK): Fraction of Dose Excreted in Urine (Feur)Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [¹⁴C]-LOXO-783, LOXO-783, [¹⁴C]-LOXO-783Healthy162023-12-23actual—2024-07-22
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)NCT04166773results2025-01-24Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver HistologyRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: Tirzepatide, PlaceboNonalcoholic Steatohepatitis1902023-12-11actual—2025-01-24
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsNCT06092931Cohort 1: Maximum Observed Plasma Concentration (Cmax) of MidazolamNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: DC-806, Midazolam, Repaglinide, Digoxin, RosuvastatinHealthy Participants282023-11-28actual—2024-01-11
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT05377333Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3457263, Placebo, DulaglutideDiabetes Mellitus, Type 2942023-11-22actual—2024-01-11
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid ArthritisNCT05516758results2025-12-04Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) Response at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Terminatedsponsor's stated reason: Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.Drug: Peresolimab, PlaceboRheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases4912023-11-20actual—2025-12-04
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)NCT05432193Treatment emergent adverse eventsOpen-label · TreatmentPhase 1Terminatedsponsor's stated reason: Business decisionDrug: [Ga-68]-PNT6555, [Lu-177]-PNT6555Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma202023-11-10actual—2025-06-25
A Study to Compare Two Formulations of LY3819469 in Healthy ParticipantsNCT05932446Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Timepoint with Measurable Concentration (AUC[0-tlast]) of LY3819469Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3819469Healthy272023-11-07actual—2024-01-05
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 DiabetesNCT04992312results2024-05-23Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Glucagon Nasal Powder [Baqsimi]Type 1 Diabetes72023-11-05actual—2024-05-23
A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male ParticipantsNCT06052462Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose AdministeredNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [14C]-LY3556050Healthy72023-11-04actual—2024-01-05
A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male ParticipantsNCT06049108Urinary Excretion of LY3871801 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose AdministeredNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [14C]-LY3871801Healthy82023-11-03actual—2024-01-08
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)NCT05706506results2024-12-13Change From Baseline in Hemoglobin A1c (HbA1c)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: TirzepatideType 2 Diabetes, Diabetes Mellitus, Type 21522023-10-31actual—2024-12-13
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy ParticipantsNCT05906836results2025-09-16Pharmacokinetics (PK): Maximum Concentration (Cmax) of RosuvastatinOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Rosuvastatin, SelpercatinibHealthy282023-10-31actual—2025-09-16
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy ParticipantsNCT06937411Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Part 1Randomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY4100511Healthy882023-10-30actual—2025-04-22
A Study of LY3871801 in Healthy Asian and Non-Asian ParticipantsNCT05960851Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3871801, PlaceboHealthy322023-10-25actual—2024-01-10
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]NCT05565742results2025-05-28Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3819469, PlaceboLipoprotein Disorder3202023-10-23actual—2025-05-28
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCNCT05291689results2024-11-26Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) ScoreOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: MORF-057Inflammatory Bowel Diseases, Colitis, Ulcerative392023-10-18actual—2026-03-11
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes MellitusNCT05596747Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3209590, Insulin GlargineDiabetes Mellitus, Type 2312023-10-10actual—2024-01-02
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male ParticipantsNCT06045000Renal Clearance (CLr) of DC-806Open-label · Basic sciencePhase 1CompletedDrug: DC-806, [14C]-DC-806Healthy Volunteers82023-10-02actual—2025-05-04
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsNCT05994807Cohort 1: Maximum Observed Plasma Concentrations (Cmax) of DC-806Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: DC-806, Itraconazole, CarbamazepineHealthy Volunteers332023-09-20actual—2023-10-04
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238results2026-07-10Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970Healthy, Obese522023-09-14actual—2026-07-10
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943Healthy, Renal Insufficiency292023-09-05actual—2023-10-02
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy ParticipantsNCT05860933Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3537982 administered with or without itraconazoleOpen-label · Basic sciencePhase 1CompletedDrug: LY3537982, Itraconazole, CarbamazepineHealthy302023-08-28actual—2024-11-08
A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseNCT03926130results2024-12-27Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)Randomized · Triple-masked · TreatmentStudy Protocol: Main ↗ · Study Protocol: Addendum ↗ · Statistical Analysis Plan: Main ↗ · Statistical Analysis Plan: Addendum ↗Phase 3CompletedDrug: Mirikizumab, Mirikizumab, Ustekinumab, Ustekinumab, Placebo, PlaceboCrohn's Disease1,1582023-08-23actual—2024-12-27
A Study of [14C]-LY3537982 in Healthy ParticipantsNCT05901311Pharmacokinetics (PK): Fraction of Dose Excreted in Urine (Feur)Non-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537982, [¹⁴C]-LY3537982, [¹⁴C]-LY3537982Healthy162023-08-10actual—2024-11-08
A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3437943, PlaceboOverweight, Obesity322023-07-27actual—2023-08-14
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).NCT05620576results2024-08-07Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3857210, PlaceboDiabetic Peripheral Neuropathic Pain1312023-07-19actual—2024-08-07
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection DevicesNCT05810597results2024-10-15Pharmacokinetics (PK): Maximum Concentration (Cmax) of TirzepatideRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Tirzepatide · Device: Single Dose Pen, Multi-use Prefilled PenHealthy652023-07-17actual—2024-10-15
A Study of Donanemab (LY3002813) in Healthy ParticipantsNCT05567159results2024-10-04Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6.Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: DonanemabHealthy422023-07-14actual—2024-10-04
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy ParticipantsNCT05894928Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LOXO-783Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LOXO-783, CholestyramineHealthy212023-07-09actual—2023-09-26
A Relative Bioavailability Study of LY3209590 in Healthy ParticipantsNCT05615532Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3209590Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3209590 (SC), LY3209590 (IV)Healthy1682023-06-28actual—2024-06-12
A Study of LY3305677 in Participants With Obesity Or OverweightNCT05623839Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3305677, PlaceboOverweight, Obesity322023-06-27actual—2023-07-05
A Study of Tirzepatide (LY3298176) in Participants With Obesity DiseaseNCT04844918results2024-07-16Mean Percent Change in Body WeightRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide · Other: PlaceboObesity2672023-06-24actual—2024-07-16
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose AdministeredNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [¹⁴C]-LY3437943Healthy72023-06-23actual—2023-07-05
A Multiple-Dose Study of LY3493269 in Healthy ParticipantsNCT05794243results2025-01-14Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of LY3493269Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1Terminatedsponsor's stated reason: Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.Drug: LY3493269, Sodium Caprate (C10), Salcaprozate Sodium (SNAC)Healthy422023-06-20actual—2025-01-14
A Study of the Effect of Food on LY3537982 in Healthy ParticipantsNCT05824858Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf])Randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3537982Healthy482023-06-17actual—2023-09-29
Study of Oral LOXO-338 in Patients With Advanced Blood CancersNCT05024045Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338Randomized · Open-label · TreatmentPhase 1CompletedDrug: LOXO-338, PirtobrutinibLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell272023-06-14actual—2026-07-17
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back PainNCT05630196results2024-08-13Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3857210, PlaceboChronic Low-back Pain1382023-06-09actual—2024-08-13
A Study of LY3457263 in Obese ParticipantsNCT05582096Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3457263, Tirzepatide, PlaceboOverweight, Obesity382023-06-08actual—2023-07-18
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis PainNCT05620563results2024-06-26Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3857210, PlaceboOsteoarthritis1472023-06-05actual—2024-06-26
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy ParticipantsNCT05644353results2025-03-28Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution FormulationRandomized · Single-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: MirikizumabHealthy4502023-05-25actual—2025-03-28
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineNCT05127486results2024-06-18Percentage of Participants With 50% Response Rate Across the 3-month Treatment Period.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: Galcanezumab, Rimegepant, Placebo, PlaceboMigraine, Episodic Migraine5802023-05-23actual—2024-06-28
A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerNCT04158700Number of Participants with Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentPhase 1/2Withdrawnsponsor's stated reason: The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.Drug: LY3200882, PembrolizumabAdvanced Cancer02023-05-11—2020-02-19
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossNCT04660643results2024-05-22Percent Change From Randomization in Body Weight at Week 88Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide · Other: PlaceboObesity, Overweight7832023-04-25actual—2024-05-22
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramNCT04657016results2024-05-16Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide · Other: PlaceboObesity, Overweight5792023-04-20actual—2024-05-16
A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male ParticipantsNCT05749848Urinary Excretion of LY3372689 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose AdministeredNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: [¹⁴C]-LY3372689Healthy82023-04-18actual—2023-04-20
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)NCT04849416results2024-07-16Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review CommitteeOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LOXO-305Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell872023-04-10actual—2026-02-06
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGSNCT04517253results2022-12-21Change From Baseline in Mean Daily Diary Scores in Participants With CANDLE (Primary Treatment Period)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2/3Terminatedsponsor's stated reason: The study was terminated due to efficacy/effectiveness reasonsDrug: BaricitinibNakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome102023-04-04actual—2025-07-10
A Study of Continuous Blood Pressure Monitoring in Healthy ParticipantsNCT05692869The Mean Change in Systolic Blood Pressure (SBP) Using Chest Patch DeviceRandomized · Open-label · Basic scienceNot applicableCompletedDrug: Propranolol, Pseudoephedrine · Device: ABPM and Wearable Novel Devices · Other: No InterventionHealthy242023-04-04actual—2023-04-13
A Drug Interaction Study of LY3871801 in Healthy ParticipantsNCT05602675Part 1: Pharmacokinetics (PK): Maximum Concentration (Cmax) of MethotrexateNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, RepaglinideHealthy392023-03-29actual—2023-04-18
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightNCT04657003results2024-04-08Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide · Other: PlaceboType 2 Diabetes, Overweight, Obesity9382023-03-16actual—2024-04-08
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)NCT04004611results2023-10-27Pharmacokinetics (PK): Clearance of MirikizumabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: MirikizumabUlcerative Colitis262023-03-15actual—2024-03-26
A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese ParticipantsNCT05440136Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3462817 (SC), Placebo (SC), LY3462817 (IV), Placebo (IV)Healthy332023-03-08actual—2023-03-30
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 DiabetesNCT05262387results2024-09-03Pharmacodynamics (PD): Change in Plasma Glucose (PG) From the Start to the End of ExerciseRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction, Lyumjev with 100% basal rate reductionDiabetes Mellitus, Type 1252023-03-07actual—2024-09-03
A Study of LY3537021 in Healthy ParticipantsNCT05444569Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3537021, Liraglutide, PlaceboHealthy472023-02-24actual—2023-03-01
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of MidazolamNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3437943, Midazolam, Warfarin, CaffeineObesity322023-02-24actual—2023-04-18
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial SarcomaNCT04145700results2023-09-13Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Terminatedsponsor's stated reason: Study terminated for meeting protocol specified futility criteria.Drug: Ramucirumab, Gemcitabine, DocetaxelSynovial Sarcoma232023-02-23actual—2023-09-13
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 IllnessNCT04427501results2022-03-07Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo GroupsRandomized · Double-masked · TreatmentStudy Protocol: Protocol J2W-MC-PYAB (m) ↗ · Study Protocol: PYAB 05 Protocol Addenda (2.2) ↗ · Study Protocol: J2W-MC-PYAB Addendum (4.2) ↗ · Statistical Analysis Plan: J2W-MC-PYAB Statistical Analysis Plan (V8) ↗ · Statistical Analysis Plan: J2W-MC-PYAB Statistical Analysis Plan Version 9 ↗ · Statistical Analysis Plan: J2W-MC-PYAB Statistical Analysis Plan A ddendum 4 ↗Phase 2/3CompletedDrug: LY3819253, LY3832479, LY3853113, PlaceboCOVID-193,3072023-02-21actual—2024-04-11
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy ParticipantsNCT05515601results2024-07-05Pharmacokinetics (PK): Maximum Concentration (Cmax) of MirikizumabRandomized · Single-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: MirikizumabHealthy3962023-02-20actual—2024-07-05
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsNCT05573230results2026-05-26Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Midazolam, LY3502970, CyclosporineHealthy322023-01-17actual—2026-05-26
A Study of Abemaciclib in Indian Women With Advanced Breast CancerNCT04707196results2023-11-21Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse EventOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4CompletedDrug: Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), FulvestrantBreast Neoplasms, Neoplasm Metastasis2002023-01-09actual—2023-11-24
A Study of Donanemab (LY3002813) in Healthy Chinese ParticipantsNCT05533411results2024-10-04Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Donanemab, PlaceboHealthy362023-01-05actual—2024-10-04
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossNCT02008357results2023-12-28Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Placebo, SolanezumabCognition Disorders1,1692022-12-27actual—2026-08-03
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)NCT05024032results2024-01-19Mean Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, PlaceboObesity, Overweight, Metabolism and Nutrition Disorder2102022-12-27actual—2024-01-19
A Study of Effect of LY3556050 on Metformin in Healthy ParticipantsNCT05615467Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of MetforminNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3556050, Metformin, IohexolHealthy182022-12-27actual—2023-01-18
A Study of Tirzepatide in Overweight and Very Overweight ParticipantsNCT04311411results2024-05-22Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Tirzepatide, Placebo, LiraglutideObesity, Overweight1142022-12-16actual—2024-05-22
A Study of LY3857210 in Healthy ParticipantsNCT05292040Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scanNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3857210Healthy102022-12-14actual—2023-03-01
A Study of LY3526318 in Healthy Male Japanese ParticipantsNCT05580250Part A and B: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1Withdrawnsponsor's stated reason: The sponsor made a business decision to withdraw the trial.Drug: LY3526318, Placebo, Iohexol, Simvastatin, MetforminHealthy02022-12-08actual—2023-01-09
A Study of Imlunestrant (LY3484356) in Healthy WomenNCT05509816results2025-11-12Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of MidazolamOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Midazolam, ImlunestrantHealthy202022-11-30actual—2025-11-12
A Study of LY3361237 in Participants With PsoriasisNCT04975295Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3361237, PlaceboPsoriasis212022-11-29actual—2022-12-05
A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryNCT04647487results2025-11-12Percent Change From Baseline in Estrogen Receptor (ER) ExpressionRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3484356Breast Cancer872022-11-11actual—2025-11-12
A Study of LY3451838 in Participants With MigraineNCT04498910results2023-11-28Change From Baseline in the Number of Monthly Migraine Headache Days During 1-MonthRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3451838, PlaceboMigraine382022-11-09actual—2023-11-28
A Study of LY3819469 in Healthy ParticipantsNCT04914546Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3819469, PlaceboHealthy662022-11-09actual—2022-11-21
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126results2026-05-27Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970, ClarithromycinHealthy262022-11-03actual—2026-05-27
A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsNCT05444556results2025-12-12Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, DigoxinHealthy1132022-11-02actual—2025-12-12
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia ANCT04541628results2024-09-04Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗Phase 1/2Terminatedsponsor's stated reason: SIG-001 programme terminatedCombination product: SIG-001Hemophilia A32022-10-28actual—2024-09-04
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes MellitusNCT04957914Incidence of Documented HypoglycemiaNon-randomized · Open-label · Basic sciencePhase 1CompletedDrug: Insulin Glargine, LY3209590Type 2 Diabetes Mellitus542022-10-17actual—2022-11-16
A Study of LY3509754 in Healthy Non-Japanese and Japanese ParticipantsNCT04586920results2025-01-03Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1Terminatedsponsor's stated reason: Terminated due to safety findingsDrug: LY3509754, Placebo, Itraconazole, MidazolamHealthy1042022-10-14actual—2025-01-03
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic PainNCT05177094results2023-11-22Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3526318, PlaceboDiabetic Peripheral Neuropathic Pain1552022-10-13actual—2023-11-22
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without MetforminNCT04537923results2023-11-02Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Tirzepatide, Insulin Lispro (U100)Type 2 Diabetes1,4282022-10-11actual—2023-11-02
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesNCT04809220results2023-09-21Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Dulaglutide, Oral antihyperglycemicsDiabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents, Type 2 Diabetes Mellitus (T2DM)5912022-10-01actual—2024-05-22
A Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719results2023-10-17Change From Baseline in HbA1c in LY3502970 as Compared to PlaceboRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3502970, Dulaglutide, Placebo, PlaceboType 2 Diabetes3832022-09-30actual—2023-10-17
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)NCT05108922results2023-11-02Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus AducanumabRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Donanemab, AducanumabMild Cognitive Impairment (MCI), Alzheimer Disease1482022-09-09actual—2024-11-29
A Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05313802results2026-05-26Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970Healthy, Obese722022-09-09actual—2026-05-26
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445results2026-07-16Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970, PlaceboDiabetes Mellitus, Type 2622022-09-05actual—2026-07-16
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089results2026-05-27Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: LY3502970Healthy392022-09-01actual—2026-05-27
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesNCT05051579results2023-09-13Percent Change From Baseline in Body Weight in LY3502970 and PlaceboRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3502970, PlaceboObesity, Overweight and Obesity2722022-08-25actual—2023-09-13
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisNCT06808815Part 1: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug.Randomized · Double-masked · TreatmentPhase 1CompletedDrug: DC-806 · Other: PlaceboPlaque Psoriasis1042022-08-23actual—2025-02-05
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)NCT04626297results2023-08-28Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine AdministrationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Lebrikizumab, PlaceboAtopic Dermatitis2542022-08-03actual—2023-10-17
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisNCT04760314results2023-08-23Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Lebrikizumab, Placebo, Topical CorticosteroidDermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic2862022-07-31actual—2023-08-23
A Device Study in Healthy ParticipantsNCT04848402Number of Participants with One or More Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to DeviceRandomized · Open-label · Basic sciencePhase 1CompletedDevice: On-Body Delivery System (OBDS)/Multiple Bolus Injector, Single Auto Injector · Drug: PlaceboHealthy602022-07-22actual—2023-03-01
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785results2023-07-03Change From Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3437943, Dulaglutide, PlaceboType 2 Diabetes2812022-07-08actual—2023-07-03
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3437943, PlaceboDiabetes Mellitus, Type 2642022-06-23actual—2022-08-22
A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy ParticipantsNCT05069896results2025-03-04Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AIRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Mirikizumab Prefilled Syringe, Mirikizumab AutoinjectorHealthy2372022-06-22actual—2025-03-04
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back PainNCT05086289results2023-10-05Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3526318, PlaceboChronic Low-back Pain1592022-06-17actual—2023-10-05
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic PainNCT04707157results2023-11-02Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Terminatedsponsor's stated reason: The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.Drug: LY3556050, PlaceboDiabetic Peripheral Neuropathic Pain682022-06-13actual—2023-11-02
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 DiabetesNCT04864977Percentage of Participants with Type 2 Diabetes Who Achieve Nadir Glucose in Range 70-125 milligram/deciliter (mg/dL)Open-label · TreatmentPhase 4Withdrawnsponsor's stated reason: Study was stopped prior to study start date due to business decision.Drug: Basal InsulinType 2 Diabetes, Type 2 Diabetes Treated With Insulin02022-06-06—2021-08-24
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With OsteoarthritisNCT05080660results2023-09-06Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3526318, PlaceboOsteoarthritis, Osteo Arthritis Knee1602022-06-06actual—2024-07-17
A Study of LY3540378 in Healthy ParticipantsNCT04768855Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3540378, Placebo, LY3540378Healthy1342022-05-30actual—2022-06-21
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using TirzepatideNCT04081337results2024-02-08Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1CompletedDrug: Tirzepatide, PlaceboObesity552022-05-26actual—2024-02-08
A Study of LY3561774 in Participants With DyslipidemiaNCT04644809Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic sciencePhase 1CompletedDrug: LY3561774, PlaceboDyslipidemias742022-05-17actual—2022-08-10
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760results2023-09-13Mean Percent Change From Baseline in Body WeightRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: LY3437943, PlaceboObesity, Overweight3382022-05-16actual—2023-09-13
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 DiabetesNCT04591626results2023-05-24Change From Baseline in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Dulaglutide, Placebo, Insulin GlargineType 2 Diabetes Mellitus2912022-04-28actual—2023-05-24
A Study Comparing Different Formulations of LY3410738 in Healthy Adult ParticipantsNCT06181084Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Hour 0 to the Last Measurable Concentration (AUC0-tlast) of LY3410738 Tablets Versus CapsulesRandomized · Open-label · Basic sciencePhase 1CompletedDrug: LY3410738, EsomeprazoleHealthy602022-04-28actual—2023-12-26
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerNCT04408924results2023-05-24Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2CompletedDrug: AbemaciclibMetastatic Castration-Resistant Prostate Cancer442022-04-27actual—2024-06-25
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisNCT03952559results2023-06-29Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point ImprovementRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedDrug: Baricitinib, Placebo, Topical corticosteroidAtopic Dermatitis5162022-04-24actual—2026-08-05
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisNCT04250350results2023-02-24Percentage of Participants Discontinued From Study Treatment Due to Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3CompletedBiological: LebrikizumabAtopic Dermatitis2062022-04-20actual—2023-02-24

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19

Related →Filings market-wide (EVX)Red flags (FLAG)Documents (DOC)Legal & controls (LGCT)